Cargando…
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment
BACKGROUND AND PURPOSE—: Poststroke cognitive impairment is a debilitating consequence of stroke. The aim of this study was to assess whether Actovegin confers cognitive benefit in patients who have had an ischemic stroke. METHODS—: This was a 12-month, parallel-group, randomized, multicenter, doubl...
Autores principales: | Guekht, Alla, Skoog, Ingmar, Edmundson, Sally, Zakharov, Vladimir, Korczyn, Amos D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404405/ https://www.ncbi.nlm.nih.gov/pubmed/28432265 http://dx.doi.org/10.1161/STROKEAHA.116.014321 |
Ejemplares similares
-
A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design
por: Guekht, Alla, et al.
Publicado: (2013) -
Actovegin® reduces PMA-induced inflammation on human cells
por: Reichl, Franz-Xaver, et al.
Publicado: (2020) -
Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients
por: Ziegler, Dan, et al.
Publicado: (2009) -
Correction to: Actovegin® reduces PMA‑induced inflammation on human cells
por: Reichl, Franz-Xaver, et al.
Publicado: (2021) -
Actovegin in the management of patients after ischemic stroke: A systematic review
por: la Fleur, Philip, et al.
Publicado: (2022)